Variables before defibrotide (DF) treatment and day +100 survival (univariate analysis; N = 88)
. | n . | Day + 100 survival, % . | P . |
---|---|---|---|
Patient characteristics | |||
Age, y | |||
Younger than 18 | 29 | 51.7 | .033* |
18 or older | 59 | 27.1 | |
Sex | |||
Female | 41 | 31.7 | .655 |
Male | 47 | 38.3 | |
Diagnosis | |||
Nonmalignant | 8 | 50 | .001* |
Hematologic malignancy | 63 | 23.8 | |
Nonhematologic malignancy | 17 | 70.6 | |
Graft | |||
Auto | 28 | 53.6 | .018* |
Allo | 60 | 26.7 | |
No. BMT | |||
More than 1 | 14 | 50 | .233 |
1 | 74 | 32.4 | |
AST elevation preconditioning | |||
No | 69 | 34.8 | 1.000 |
Yes | 19 | 36.8 | |
Conditioning regimen | |||
Cy | |||
No | 22 | 27.3 | .446 |
Yes | 66 | 37.9 | |
Bu | |||
No | 41 | 48.8 | .015* |
Yes | 47 | 23.4 | |
TBI | |||
No | 59 | 33.9 | .813 |
Yes | 29 | 37.9 | |
Characteristics of VOD | |||
RUQ pain | |||
No | 18 | 27.8 | .584 |
Yes | 70 | 37.1 | |
Ascites | |||
No | 14 | 28.6 | .762 |
Yes | 74 | 36.5 | |
Hepatomegaly | |||
No | 24 | 25 | .317 |
Yes | 64 | 37.5 | |
Portal flow | |||
Normal | 57 | 28.1 | .066 |
Abnormal | 31 | 48.4 | |
Prior t-PA/heparin | |||
No | 74 | 29.7 | .029* |
Yes | 14 | 64.3 | |
Abnormal creatinine | |||
No | 23 | 39.1 | .800 |
Yes | 65 | 33.8 | |
Oxygen requiring | |||
No | 24 | 50 | .086 |
Yes | 64 | 29.7 | |
Encephalopathy | |||
No | 56 | 41.1 | .166 |
Yes | 32 | 25 | |
No. of systems as part of MOF (liver + renal + pulmonary + CNS) | |||
2 or fewer | 30 | 46.7 | .065 |
More than 2 | 58 | 29.3 |
. | n . | Day + 100 survival, % . | P . |
---|---|---|---|
Patient characteristics | |||
Age, y | |||
Younger than 18 | 29 | 51.7 | .033* |
18 or older | 59 | 27.1 | |
Sex | |||
Female | 41 | 31.7 | .655 |
Male | 47 | 38.3 | |
Diagnosis | |||
Nonmalignant | 8 | 50 | .001* |
Hematologic malignancy | 63 | 23.8 | |
Nonhematologic malignancy | 17 | 70.6 | |
Graft | |||
Auto | 28 | 53.6 | .018* |
Allo | 60 | 26.7 | |
No. BMT | |||
More than 1 | 14 | 50 | .233 |
1 | 74 | 32.4 | |
AST elevation preconditioning | |||
No | 69 | 34.8 | 1.000 |
Yes | 19 | 36.8 | |
Conditioning regimen | |||
Cy | |||
No | 22 | 27.3 | .446 |
Yes | 66 | 37.9 | |
Bu | |||
No | 41 | 48.8 | .015* |
Yes | 47 | 23.4 | |
TBI | |||
No | 59 | 33.9 | .813 |
Yes | 29 | 37.9 | |
Characteristics of VOD | |||
RUQ pain | |||
No | 18 | 27.8 | .584 |
Yes | 70 | 37.1 | |
Ascites | |||
No | 14 | 28.6 | .762 |
Yes | 74 | 36.5 | |
Hepatomegaly | |||
No | 24 | 25 | .317 |
Yes | 64 | 37.5 | |
Portal flow | |||
Normal | 57 | 28.1 | .066 |
Abnormal | 31 | 48.4 | |
Prior t-PA/heparin | |||
No | 74 | 29.7 | .029* |
Yes | 14 | 64.3 | |
Abnormal creatinine | |||
No | 23 | 39.1 | .800 |
Yes | 65 | 33.8 | |
Oxygen requiring | |||
No | 24 | 50 | .086 |
Yes | 64 | 29.7 | |
Encephalopathy | |||
No | 56 | 41.1 | .166 |
Yes | 32 | 25 | |
No. of systems as part of MOF (liver + renal + pulmonary + CNS) | |||
2 or fewer | 30 | 46.7 | .065 |
More than 2 | 58 | 29.3 |
BMT indicates bone marrow transplantation; AST: aspartate transferase; and CNS, central nervous system.
Significant at .05 level.